Evolent has more than 1,400 clinicians—including 300 physicians—focused on improving health outcomes for cancer, cardiovascular disease, musculoskeletal conditions and more. Watch to learn how our evidence-driven, patient-first model helps produce more informed treatment decisions.
Other content in this Stream
Company's solutions are coming together to improve outcomes for people living with complex health conditions.
Our CMO, Dr. Andrew Hertler, talks to Yahoo Life about identifying which patients need genetic testing or aggressive cancer screening, the issues surrounding prophylactic surgery, and more.
Becker's highlights our CMO's predictions on the future of health care.
Dr. Andrew Hertler discussed the importance of prophylactic mastectomy for individuals carrying BRCA1, BRCA2 and other deleterious mutations.
Our vice president of pharmacy explores the hard-to-predict impacts of drug price negotiations on consumers, plans and pharmaceutical companies.
Our CMO speaks with Urban Health Today about who should get screened, the role of primary care physicians in identifying at-risk individuals, and more.
Two Evolent experts discuss the benefits of genetic testing in oncology in American Journal of Managed Care.
Evolent takes a multifaceted approach to help providers navigate shortages of cisplatin, carboplatin and other anti-cancer drugs.
Our chief strategy officer speaks with Becker's about the largely untapped potential of value-based specialty care.
Oncology Care Partners CEO Erich Mounce describes how his practices are purpose-built for value.
Evolent is leveraging our expertise in two key specialties to reduce cardiovascular damage related to cancer drugs.
An Evolent program reduces unnecessary radiation treatments for breast cancer without compromising efficacy.
Evolent's Connie Ducaine writes in MarketWatch that patients need to be proactive to ensure their preferences for end of life are respected.
Our solutions are coming together under one brand to improve outcomes for people with complex health conditions.
Evolent addresses a startling difference in what men and women pay for the same drug.
Our chief medical officer shares three trends likely to impact oncology drug spend in the near future.